cobas® TaqScreen DPX Test

Real-time discrimination of B19V and HAV in one assay

Image of cobas® TaqScreen DPX test for the detection of parvovirus B19 and HAV in laboratory tests.

Real-time discrimination of B19V and HAV in one assay

Increasing the safety of human plasma and plasma products


The cobas® TaqScreen DPX Test a real-time polymerase chain reaction (PCR) assay that detects parvovirus B19 (B19V) and hepatitis A virus (HAV) in human plasma.

Designed to run on the cobas s 201 system, the cobas® TaqScreen DPX Test can help manage the B19V burden in plasma pools and identify HAV-contaminated units while increasing processing efficiency.

Features and benefits

  • Simultaneously quantifies B19V DNA and detects HAV RNA in real-time
  • Detects B19V genotypes 1, 2 and 3 and HAV genotypes I, II, III
  • Available as a B19V DNA-only quantitative assay or a dual/result B19V DNA titer and a HAV RNA reactive/non-reactive
  • Ready-to-use reagents that do not require freezing
Intended use

Intended use

The cobas® TaqScreen DPX Test, for use on the cobas s 201 system, is an in vitro nucleic acid amplification test for the direct quantitation of human parvovirus B19 (B19V) DNA (genotypes 1, 2, and 3) and the direct qualitative detection of hepatitis A virus (HAV) RNA (genotypes I, II, and III) in human plasma.

Registration status

*This test is not an FDA-licensed product. It is available to US laboratories with appropriate FDA authorization.

*DPX has been submitted to the FDA as a Master File and will not have a regulatory classification; it will not be cleared, licensed or approved by the FDA.